Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, People's Republic of China; Department of Lung Cancer Center, West China Hospital, Sichuan University, Chengdu, People's Republic of China.
Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, People's Republic of China.
Pathol Res Pract. 2023 Feb;242:154314. doi: 10.1016/j.prp.2023.154314. Epub 2023 Jan 16.
Considerable evidence has verified that the micropapillary pattern is significantly associated with worse prognosis in pulmonary adenocarcinoma. However, whether the presence of a micropapillary component in pathological stage IA lung adenocarcinoma is also related to worse prognosis remains unclear up to now. The aim of this meta-analysis was to identify the prognostic role of presence of a micropapillary component in pathological stage IA lung adenocarcinoma patients. Relevant studies were searched from the PubMed, EMBASE, Web of Science and CNKI databases and reviewed. The primary and secondary outcomes were the recurrence risk and long-term survival including the overall survival (OS) and disease-free survival (DFS), respectively. All statistical analysis were conducted by STATA 12.0 software. A total of 5257 lung adenocarcinoma patients at the pathological stage IA from ten retrospective studies were enrolled. The recurrence rates in pathological stage IA lung adenocarcinoma patients with and without the a micropapillary component were 32% [95% confidence interval (CI): 20%- 44%] and 7% (95% CI: 4%-10%) separately and pooled results indicated that presence of a micropapillary component was an obvious risk factor for recurrence [odds ratio (OR)= 3.41, 95% CI: 2.80-4.16, P<0.001]. Besides, the presence of a micropapillary component was significantly related to poorer OS [hazard ratio (HR)= 2.44, 95% CI: 1.28-4.68, P = 0.007] and DFS (HR=2.60, 95% CI: 1.63-4.16, P<0.001). Subgroup analysis focusing on invasive adenocarcinoma manifested consistent results. In pathological stage IA lung adenocarcinoma, the presence of a micropapillary component predicts obviously higher recurrence risk and worse prognosis even after focusing on invasive adenocarcinoma. However, more prospective high-quality studies are still needed to verify our findings.
大量证据已经证实,微乳头状模式与肺腺癌的预后不良显著相关。然而,病理分期 IA 肺腺癌中是否存在微乳头状成分也与预后不良有关,目前尚不清楚。本荟萃分析的目的是确定病理分期 IA 肺腺癌患者中存在微乳头状成分的预后作用。从 PubMed、EMBASE、Web of Science 和中国知网数据库中搜索相关研究,并进行综述。主要和次要结局分别为复发风险和长期生存,包括总生存(OS)和无病生存(DFS)。所有统计分析均采用 STATA 12.0 软件进行。共纳入 10 项回顾性研究的 5257 例病理分期 IA 肺腺癌患者。病理分期 IA 肺腺癌患者中存在和不存在微乳头状成分的复发率分别为 32%(95%可信区间:20%-44%)和 7%(95%可信区间:4%-10%),汇总结果表明存在微乳头状成分是复发的明显危险因素[优势比(OR)=3.41,95%可信区间:2.80-4.16,P<0.001]。此外,存在微乳头状成分与较差的 OS 显著相关[风险比(HR)=2.44,95%可信区间:1.28-4.68,P=0.007]和 DFS(HR=2.60,95%可信区间:1.63-4.16,P<0.001)。针对浸润性腺癌的亚组分析显示出一致的结果。在病理分期 IA 肺腺癌中,即使针对浸润性腺癌,存在微乳头状成分也明显预示着更高的复发风险和更差的预后。然而,仍需要更多前瞻性高质量研究来验证我们的发现。